Your IGF-1 will not budge. Your growth hormone looks fine, maybe even high. You are on a plan meant to support the growth-hormone axis, and the lab number everyone watches as a "working" marker keeps stalling.
That pattern often triggers the wrong next move: a bigger stack, a higher dose, another vial. Sometimes the better first question is simpler.
How do you take your estrogen?
Oral estrogen and transdermal estradiol are not the same for the GH/IGF-1 axis. Route is not a footnote. For many midlife and postmenopausal women chasing body composition, recovery, or IGF-1 on a peptide plan, it is part of the foundation.
A familiar stall
Picture a midlife woman on oral estrogen for HRT. She starts a growth-hormone-axis plan with her clinician. Sleep and training look reasonable. Upstream GH-related signals look active. IGF-1 barely moves.
The instinct is to blame the peptide. The more useful question is what her liver is hearing first. Swallowed estrogen arrives at the liver in a concentrated first pass before the rest of the body sees a steady level. Circulating IGF-1 is largely made in the liver in response to GH. Change that first-pass load, and you can change the readout people watch. That is why route belongs in the differential when IGF-1 stalls, not because estrogen is the enemy, but because delivery shape matters at the organ that makes the marker. If you have been chasing a higher IGF-1 without asking how your estrogen is delivered, this is the conversation to have next.
Why swallowed estrogen can lower IGF-1
When you swallow estrogen, your liver sees a high load on that first pass. That tends to lower hepatic IGF-1 production. Classic comparative work in postmenopausal women mapped this decades ago: oral estrogen and transdermal estradiol do not do the same thing to 24-hour GH secretion and IGF-1.
One plain-language mechanism from later review work: estrogen can turn on a brake inside liver cells (SOCS-2) that muffles GH's message. The signal arrives. The factory answer stays softer.
The same hepatic first-pass story also shows up elsewhere on oral estrogen. Clotting factors, CRP, and SHBG can shift when the liver sees that swallowed load. We covered the clot and stroke education angle separately in Does Estrogen Cause Blood Clots and Strokes? What the Actual Trial Data Shows. The IGF-1 piece is another chapter of that same liver conversation.
Not just one pill quirk
It is tempting to blame a single formulation and stop thinking. The classic Weissberger comparison used oral ethinyl estradiol at 20 mcg, not oral estradiol. That matters for honesty about what was studied.
Follow-up work by Kelly and colleagues compared oral ethinyl estradiol, conjugated equine estrogen, and oral estradiol valerate. All of them reduced IGF-1 in postmenopausal women. The shared feature was the oral route and the hepatic hit, not an ethinyl-estradiol-only quirk.
So if you are on oral estrogen for HRT, or on an ethinyl estradiol contraceptive, the same first-pass conversation applies. Formulation details still matter clinically. The hepatic story is bigger than one brand name.
Ethinyl estradiol is a special case
Ethinyl estradiol resists liver breakdown. That is why it is potent at low doses, and why a contraceptive patch or vaginal ring that still delivers ethinyl estradiol can hit the liver hard enough to raise SHBG and related markers. Switching from an oral ethinyl estradiol pill to a patch or ring does not fix ethinyl estradiol the way moving from oral estradiol to transdermal estradiol often can. Molecule and route both matter. Do not treat every "non-oral" product as first-pass spared.
High GH, soft IGF-1
Here is the part that confuses people most.
Oral estrogen can raise GH while IGF-1 falls.
Lower circulating IGF-1 reduces negative feedback on the pituitary. GH secretion may climb even as the liver is making less IGF-1. You can see a teachable route signature: higher GH tone with a softer IGF-1 readout.
That pattern is not proof your axis is healthy. It is not proof GH is "destroyed." Often GH is up. The liver's answer into IGF-1 is down. If you only glance at one number, you miss the mismatch.
What the classic patch trials actually used
The landmark Weissberger and Ho comparisons used transdermal estradiol patches (Weissberger: 100 mcg twice weekly), not gels or creams. In those data, usual-dose patch estradiol largely spared the first-pass IGF-1 drop, and often moved IGF-1 toward a more youthful range without the same GH rise oral estrogen produced.
In clinic we often use gels or creams as other transdermal forms that also skip that swallowed first-pass. Prefer the word "transdermal" for that shared delivery idea. Compounded cream absorption is more variable and less studied than the patch trials, so do not treat every cream dose as identical to the classic patch evidence. High systemic estrogen exposure can still matter at any route. The practical teaching point is simpler: usual transdermal replacement largely skips the liver-first hit that oral estrogen creates.
Same GH signal, smaller IGF-1 answer
Route does not only change baseline IGF-1. It can change how the same GH dose lands.
In growth-hormone-deficient women, the same GH dose raised IGF-1 less on oral estrogen than on transdermal estrogen. Metabolic GH actions such as fat oxidation and protein synthesis were likewise antagonized on oral estrogen. That is GH-therapy physiology with a clear route contrast.
If oral estrogen can blunt the liver's answer to therapeutic GH, it is reasonable to ask what that means when you are trying to raise IGF-1 with a growth-hormone-axis peptide. Many of those peptides work by increasing GH tone upstream. Circulating IGF-1 is largely the liver's answer to that signal. If oral estrogen is damping that answer, the lab IGF-1 may stall even when the upstream signal looks active.
That is physiologic inference from estrogen-route and GH-therapy data. It is not a claim that any named peptide was proven in a head-to-head oral-estrogen trial, and it is not a promise that switching route always raises IGF-1.
This piece is one concrete chapter of a broader idea we covered earlier: foundation first. Peptides are signals. The terrain they land in decides how loudly they register. For the wider sequencing frame (thyroid, sex steroids, insulin tone, sleep), see Foundation First: Why Peptides Don't Work Without Hormone Optimization.
What to expect and how we monitor
If you are on oral estrogen and IGF-1 has stalled on a GH-axis plan, the first move is usually a route conversation, not another vial. Review how you take estrogen. If a switch to a transdermal form makes clinical sense for you, reassess IGF-1 and the rest of the picture after the foundation piece is clear. Get that route picture straight before you add another signal.
Expect honest monitoring, not guaranteed deltas. IGF-1 is a marker, not an outcome. A lower IGF-1 on oral estrogen alone has not been shown to prove clinical harm, and a higher IGF-1 is not simply better. Watch the trend with your clinician alongside body composition, recovery, lipids, glucose tone, and how you feel. One lab number is not the whole story. Some women need and benefit from thoughtful estrogen therapy either way. Estrogen is not the villain here. Delivery shape is the question when IGF-1 and GH-axis response are also on the table.
This education is aimed at midlife and postmenopausal women on oral estrogen (HRT or ethinyl estradiol contraception) who are chasing IGF-1, body composition, or GH-axis response, and at women on GH replacement where oral estrogen raises the dose needed to move IGF-1. It is not a vignette for men, pregnancy, or untreated cancer contexts.
A short caveat: this is physiology and clinical sequencing education, not dosing guidance, not a stack recipe, and not a promise that oral-to-transdermal always raises IGF-1 or makes peptides work. Some peptide use is off-label or investigational and belongs with a licensed physician who knows your labs and history.
If IGF-1 has stalled while you are on oral estrogen and a GH-axis plan, start with the route conversation. Then rebuild the foundation picture before you add another signal.
A free consultation is a good place to start that conversation, no commitment required, just a chance to look at the full picture together. To request one, email drwilcox@precisionhormoneconsulting.com.
Darrell Wilcox, MD | @wellnessdoc_4everyoung on Instagram
References
Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991. PMID: 1991807.
Kelly JJ, et al. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin Endocrinol (Oxf). 1993. PMID: 8252746.
Ho KK, et al. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res. 1992. PMID: 1642149.
Wolthers T, et al. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab. 2001. PMID: 11701433.
Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004. PMID: 15466938.
Ho KK, O'Sullivan AJ, Weissberger AJ, Kelly JJ. Sex steroid regulation of growth hormone secretion and action. Horm Res. 1996. PMID: 8742122.
This content is for educational purposes only and does not constitute medical advice. Estrogen route, IGF-1, and peptide or growth-hormone plans deserve individualized evaluation with a licensed clinician who knows your labs and history. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas and Arizona.
